HCR 557 Module 6 Paper 3: Local and International Studies Example

One Protocol, Four Countries: Challenges, Design and a Protocol Abstract for a Multiregional Trial

Student Name

MS in Clinical Research Management, Arizona State University

HCR 557: Clinical Research Design and Methods

Instructor Name

Month Day, Year

One Protocol, Four Countries: Challenges, Design and a Protocol Abstract for a Multiregional Trial

Introduction

Sponsors increasingly run trials in many countries at once to recruit faster and to support approval in several markets. A review of trials run by the twenty largest U.S. drug makers found that roughly a third of their Phase 3 studies took place with no U.S. site at all (Glickman et al., 2009). Running a single protocol across countries brings benefits and difficulties. This paper sets out those difficulties for a planned trial of an investigational oral drug for lateral epicondylitis, chooses a design and presents a protocol abstract.

Challenges of Global Clinical Trials

Scientific

Usual care differs between countries. Corticosteroid injection, physiotherapy and bracing are used at different rates, and background treatments can change how much a new drug appears to add. Genetic and environmental differences can alter how a drug is absorbed, metabolized or tolerated. Regulators expect sponsors to plan for regional differences in a multiregional trial, rather than discover them afterward, by pooling regions with similar intrinsic and extrinsic factors and checking consistency of effect (U.S. Food and Drug Administration, 2018).

Ethical

Informed consent must be meaningful in each language and culture. Payments that are modest in one country can be coercive in another. Participants should not bear risk for a drug they will not be able to obtain, so post-trial access deserves attention, and the standard of care offered to control participants must not fall below local norms (Glickman et al., 2009).

Regulatory

Each country has its own ethics committees, approval timelines and import rules for investigational product. For data to support U.S. approval, foreign studies not conducted under an IND must follow good clinical practice, including review by an independent ethics committee, and the FDA must be able to validate the data through on-site inspection if necessary (21 C.F.R. § 312.120).

Operational

Sites differ in research experience. Time zones complicate monitoring, translated outcome questionnaires must be validated, laboratory values need central measurement or careful standardization and drug supply has to clear customs at the right temperature on schedule.

Choosing and Justifying a Design

The chosen design is a multiregional, randomized, double-blind, placebo-controlled, parallel-group trial with randomization stratified by region and by symptom duration. A parallel design is preferred to a crossover because lateral epicondylitis often improves on its own, so a participant's state in a second period would not match the first. Placebo control is ethical because no medication has proven lasting benefit, all participants may use rescue analgesics and the condition is not dangerous. Stratifying by region keeps the arms balanced within each country, so that a regional difference in placebo response cannot masquerade as a drug effect. The sample of 244 participants calculated in Paper 2 is divided among regions, with a planned consistency analysis by region.

Protocol Abstract

Title: A Phase 2b, Multiregional, Randomized, Double-Blind, Placebo-Controlled Trial of Drug XYZ in Adults With Chronic Lateral Epicondylitis.

Objective: To test whether eight weeks of oral Drug XYZ, compared with placebo, raises the share of participants who are recovered or much improved at week 12.

Design: Randomized 1:1, double-blind, parallel-group, stratified by region and by symptom duration (6 to 12 weeks or longer).

Setting: About 24 outpatient sports medicine and primary care sites in the United States, Brazil, Poland and South Korea.

Participants: 244 adults aged 18 to 70 with unilateral lateral elbow pain for at least six weeks, confirmed on examination. Key exclusions: corticosteroid injection in the past three months, prior elbow surgery and inflammatory arthritis.

Intervention: Drug XYZ or matching placebo by mouth for eight weeks, with standardized education and rescue acetaminophen.

Primary endpoint: Proportion rating themselves completely recovered or much improved on the six-point global change scale at week 12.

Secondary endpoints: Change in a validated pain and function questionnaire, pain-free grip strength, success at 26 weeks and recurrence by 52 weeks.

Safety: Adverse events, laboratory tests at baseline, week 4 and week 8 and review by an independent data monitoring committee.

Analysis: Intention-to-treat comparison of success rates with a stratified test, alpha 0.05 two-sided, with prespecified consistency analysis by region.

Conclusion

A multiregional trial can recruit faster and serve several regulators, but only if the protocol anticipates how countries differ. A stratified, double-blind parallel design, with validated translations and central systems, addresses the main scientific risks, while careful consent, fair standards of care and attention to post-trial access address the ethical ones.

References

Foreign clinical studies not conducted under an IND, 21 C.F.R. § 312.120 (2025).

Glickman, S. W., McHutchison, J. G., Peterson, E. D., Cairns, C. B., Harrington, R. A., Califf, R. M., & Schulman, K. A. (2009). Ethical and scientific implications of the globalization of clinical research. New England Journal of Medicine, 360(8), 816-823. https://doi.org/10.1056/NEJMsb0803929

U.S. Food and Drug Administration. (2018). E17 general principles for planning and design of multi-regional clinical trials [Guidance for industry]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e17-general-principles-planning-and-design-multi-regional-clinical-trials